Abstract 180P
Background
Intrahepatic cholangiocarcinoma(iCCA) is the second most common primary hepatic malignancy after hepatocellular carcinoma (HCC), and is also a highly malignant type of tumor. It is necessary to identify novel therapeutic targets.Histidine phosphatase LHPP were reported as a tumor suppressor for Hepatocellular Carcinoma and cervical cancer. And low level LHPP enhanced cell progression and tumor formation, and was associated with poor prognosis. So, we hypothesized that LHPP might be also related to the tumorigenesis of iCCA.
Methods
We analyzed the expression and clinical significance of LHPP in TCGA cohort and patient tissues. We transfected the iCCA cell lines with LHPP over-expression lentivirus or small interfering RNA. Cell proliferation were evaluated with the CCK-8 and colony formation assays. Cell apoptosis was evaluated by Annexin V/PI staining.Transwell assays were performed to assess cell invasion. Gene Set Enrichment Analysis (GSEA) was performed to enrich genes associated with LHPP. Markers of EMT and TGFβ/SMAD3 signaling pathway were evaluated by real-time PCR and western blotting.
Results
In this study, we found the mRNA and protein level of LHPP were downregulated in tumor tissues, and low level LHPP predicted a poor survival. LHPP overexpression suppressed RBE and HCCC-9810 cells growth and colony formation, and moderately promote cell apoptosis and EMT. In contrast, accumulated cell growth, colony formation, cell invasion and EMT were observed in LHPP knock down cells. We divided samples from the TCGA-CHOL cohort into two sub-group (LHPP_low and LHPP_High) by medina expression of LHPP, and found that TGFβ signaling pathway was significantly activated in LHPP_low group. The expression of TGFβ1 was negatively correlated with LHPP. We found that the expression of TGFβ1, TGFβ1R and p-SMAD3 were downregulated in LHPP overexpression cells, and these proteins were upregulated in LHPP down-expression cells.
Conclusions
We demonstrated that LHPP also serve as a suppressor gene to inhibit cell proliferation, cell invasion and EMT. And low level LHPP which was observed in tumor tissues predicted a poor survival. Mechanically, low level LHPP activate TGFβ/SMAD3 signaling pathway.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Fudan University Shanghai Cancer Center.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
27P - The prognostic value of neutrophil to lymphocyte ratio (NLR) and 18F-FDG PET SUV in breast cancer patients underwent neoadjuvant chemotherapy
Presenter: Soong June Bae
Session: Poster display session
Resources:
Abstract
28P - Accuracy of core biopsy in predicting pathologic complete response in the breast in patients with complete/near complete clinical and radiological response (Complete Responders in the Breast – CRBr): A feasibility study
Presenter: Nisha Hariharan
Session: Poster display session
Resources:
Abstract
29P - Tumour response to neoadjuvant chemotherapy in breast cancer: Routine pathologic markers improve the predictive power of a cell-loss metric based on release of thymidine kinase 1 into blood
Presenter: Bernhard Tribukait
Session: Poster display session
Resources:
Abstract
30P - Comparison of metabolic changes between neoadjuvant chemotherapy and neoadjuvant endocrine therapy in premenopausal women with ER positive, HER2 negative breast cancer
Presenter: Ho-hyun Ryu
Session: Poster display session
Resources:
Abstract
31P - Circulating miR-155 as a potential therapeutic monitoring marker in breast cancer
Presenter: Sumadi Lukman Anwar
Session: Poster display session
Resources:
Abstract
32P - Profile of breast cancer epidemiology in Sanglah General Hospital, Denpasar, Bali from 2012 to 2019
Presenter: Citra Aryanti
Session: Poster display session
Resources:
Abstract
33P - Contrast enhanced chest CT in patients with breast cancer: Comprehensive imaging analysis and correlation with biological markers
Presenter: Bo Hwa Choi
Session: Poster display session
Resources:
Abstract
34P - Verification of metabolic regulatory mechanisms in androgen receptor-positive triple negative breast cancer
Presenter: Yuka Asano
Session: Poster display session
Resources:
Abstract
35TiP - Ribociclib plus goserelin with hormonal therapy versus physician choice chemotherapy in pre-/perimenopausal patients with HR+, HER2– inoperable locally advanced breast cancer (ABC): RIGHT choice study
Presenter: Yen-Shen Lu
Session: Poster display session
Resources:
Abstract
36TiP - A prospective study to assess response to neoadjuvant hormonal therapy in postmenopausal women with hormone-receptor positive breast cancer at a regional cancer centre in South India
Presenter: Shina Goyal
Session: Poster display session
Resources:
Abstract